Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients

被引：59

作者：

Bickel, Markus ^{[1
]}

Wieters, Imke ^{[1
]}

Khaykin, Pavel ^{[1
]}

Nisius, Gabi ^{[1
]}

Haberl, Annette ^{[1
]}

Stephan, Christoph ^{[1
]}

Von Hentig, Nils ^{[1
]}

Herrmann, Eva ^{[3
]}

Doerr, Hans W. ^{[2
]}

Brodt, Hans R. ^{[1
]}

Allwinn, Regina ^{[2
]}

机构：

[1] Goethe Univ Clin, HIVCTR, Frankfurt, Germany

[2] Goethe Univ Clin, Inst Med Virol, Frankfurt, Germany

[3] Goethe Univ Clin, Inst Biostat & Math Modeling, Frankfurt, Germany

来源：

AIDS | 2010年 / 24卷 / 09期

关键词：

H1N1; hemagglutination inhibition assay; HIV; immunoresponse; ANTIBODY-RESPONSES; IMMUNE-RESPONSE; HIV INFECTION; IMMUNOGENICITY; SUBUNIT; SAFETY; IMMUNIZATION;

D O I：

10.1097/QAD.0b013e3283398da1

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Objective: To determine rates of seroconversion after single vaccination with a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HIV-1-infected patients (ClinicalTrials. gov Identifier: NCT01017172). Design: Single center diagnostic study. Setting: Institutional HIV outpatient department of an urban university clinic. Participants: Adult HIV-1-infected individuals. Intervention: Serum samples were taken before and 21 days after vaccination. Main outcome measures: Antibody titers determined by hemagglutination inhibition assay. Seroconversion to vaccination was defined by either an antibody titer of 1 : 10 or less before and of at least 1 : 40 after or at least 1 : 10 before and at least four-fold increase in antibody titer 21 days after single vaccination. Results: One hundred and sixty patients (125 men/35 women) were analyzed. Before vaccination, 23 patients (14.4%) had a hemagglutination inhibition assay titer of at least 1 : 40. A median of 22 +/- 3 days after vaccination, 110 (69%) patients seroconverted. Seroconverters were younger (45.1 +/- 10.0 vs. 48.8 +/- 11.3 years; P = 0.04), had a higher CD4 cell count (532 +/- 227 vs. 475 +/- 281 cells/mu l; P = 0.03) and were more likely to have received a previous H5N1 vaccination in 2009 (25 vs. 8%; P = 0.02) when compared to nonresponders. No other significant differences were found comparing the two groups (prevaccination hemagglutination inhibition assay titer of >= 1 : 40, AIDS, HAART, HIV RNA PCR < 50 copies/ml or CD4 nadir, CD4 and CD8 percentage, sex, BMI, chronic hepatitis B or C). Conclusion: Seroconversion after one dose of a split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine of HIV-infected patients was 69%. Studies to investigate whether a second dose of the vaccine will increase seroconversion rate are needed. (C) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins

引用

页码：F31 / F35

页数：5

共 26 条

[11] Safety and immunogenicity of conventional subunit and MF59-adjuvanted influenza vaccines in human immunodeficiency virus-1-seropositive patients [J].